References
- Corson S. L. Impact of estrogen replacement therapy on cardiovascular risk. J. Reprod. Med. 1989; 34: 729–46, Suppl. 9
- Castelli W. P., Garrison R. J., Wilson P. W. F., Abbott R. D., Kalousdian S., Kannel W. B. Incidence of coronary heart disease and lipoprotein cholesterol levels. J. Am. Med. Assoc. 1986; 256: 2835–8
- Gordon T., Castelli W. P., Hjortland M. C., Kannel W. B., Dawber T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am. J. Med. 1977; 62: 707–14
- Fisch B., Rikover Y., Shohat L., Zurgil N., Ovadia J., Wits I. P., Yron I. The relationship between in vitro fertilization and naturally occurring antibodies; evidence for increased production of antiphospholipid autoantibodies. Fertil. Steril. 1991; 56: 718–24
- Gordon D. J., Rifkind B. M. High-density lipoprotein—the clinical implications of recent studies. N. Engl. J. Med. 1989; 321: 1311–6
- Jacobs D. R., Jr, Mebane I. L., Bangdiwala S. I., Criqui M. H., Tyroler H. A. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am. J. Epidemiol. 1990; 131: 32–47
- Kannel W. B., Castelli W. P., Gordon T., McNamara P. M. Serum cholesterol, lipoproteins, and risk of coronary heart disease: the Framingham study. Ann. Intern. Med. 1971; 74: 1–12
- Szklo M., Tonascial J., Gordis L., Bloom I. Estrogen use and myocardial infarction risk: a case—control study. Prev. Med. 1984; 13: 510–6
- Bush T. L., Fried L. P., Barrett-Connor E. Cholesterol, lipoproteins and coronary heart disease in women. Clin. Chem. 1988; 34(8B)60–70
- Walsh B. W., Schiff I., Rosner B., Greenberg L., Ravnikar V., Sacks F. M. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N. Engl. J. Med. 1991; 325: 1196–204
- Campos H., McNamara J. R., Wilson P. W., Ordovas J. M., Schaefer E. J. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J. Clin. Endocrinol. Metab. 1988; 67: 30–5
- Kuhl H. Beyond hormonal action: are oestrogens effective free radical scavengers. Maturitas 1993; 18: 5–8
- Tikkanen M. J., Nikkila E. A., Kuusi T., Sipinen S. U. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrel. J. Clin. Endocrinol. Metab. 1982; 54: 1113–7
- Lemay A., Drideau N. A., Forest J. C., Dodin S., Maheux R. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol. Clin. Endocrinol. 1991; 35: 305–10
- Archer T. K., Tam S. P., Deeley R. G. Kinetics of estrogen-dependent modulation of apolipoprotein A-1 synthesis in human hepatoma cells. J. Biol. Chem. 1986; 261: 5067–74
- Tam S. P., Archer T. K., Deeley R. G. Biphasic effect of estrogen on apolipoprotein synthesis in human hepatoma cells: mechanism of antagonism by testosterone. Biochemistry 1986; 83: 3111–5
- Brown M. S., Kovanen P. T., Goldstein J. L. Regulation of plasma cholesterol by lipoprotein receptors. Science 1981; 212: 628–35
- Burry K. A., Patton P. E., Illingworth D. R. Metabolic changes during medical treatment of endometriosis; Nafarelin acetate versus danazol. Am. J. Obstet. Gynecol 1989; 160: 1454–61
- Cirkel U., Schweppe K. W., Ochs H., Schneider H. P. G. Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriose-Behandlung mit einem LHRH-Agonisten. Geburtshilfe Fraunheilkd. 1987; 47: 154–7
- Dlugi A. M., Rufo S., D'Amico J. F., Seibel M. M. A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil. Steril 1988; 49: 913–16
- Henzl M. R., Corson S. L., Moghissi K., Buttram V. C., Berqvist C., Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N. Engl. J. Med. 1988; 318: 485–9
- Valimaki M., Nilsson C. G., Roine R., Ylikorkala O. Comparison between the effects of nafarelin and danazol on serum lipids and lipoproteins in patients with endometriosis. J. Clin. Endocrinol. Metab. 1989; 69: 1097–103